Pacira BioSciences, Inc. (PCRX)
NASDAQ: PCRX · Real-Time Price · USD
23.22
-0.46 (-1.94%)
May 29, 2026, 4:00 PM EDT - Market closed
Pacira BioSciences Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | 21.44 | -99.56 | 41.96 | 15.91 | 41.98 | 145.52 |
Depreciation & Amortization | 90.92 | 78.79 | 75.57 | 91.5 | 28.55 | 19.91 |
Stock-Based Compensation | 56.27 | 51.17 | 47.9 | 48.09 | 42.25 | 39.92 |
Other Adjustments | 15.54 | 177.51 | 35 | 6.21 | 38.45 | -94.52 |
Change in Receivables | -14.59 | -7.75 | -7.16 | -2.08 | -10.43 | -5.52 |
Changes in Inventories | -45.8 | -20.93 | -8.29 | 2.49 | -4.47 | -6.35 |
Changes in Accounts Payable | -2.99 | 3.08 | 0.92 | 6.27 | -10.26 | -3.31 |
Changes in Accrued Expenses | -7.97 | 11.72 | -22.04 | -19.86 | 5.45 | -6 |
Changes in Other Operating Activities | -11.15 | -4.65 | -9.21 | -3.26 | -5.8 | -12.62 |
Operating Cash Flow | 141.44 | 189.39 | 154.65 | 145.27 | 125.72 | 77.03 |
Operating Cash Flow Growth | -30.61% | 22.46% | 6.45% | 15.56% | 63.20% | 9.23% |
Capital Expenditures | -17.23 | -10.64 | -15.16 | -30.08 | -45.87 | -37.8 |
Purchases of Investments | -159.27 | -252.21 | -144.37 | -400.69 | -628.68 | -547.68 |
Proceeds from Sale of Investments | 273.61 | 179.57 | 237.07 | 237.58 | 1,078 | 307.87 |
Payments for Business Acquisitions | -16.7 | - | - | - | -420.04 | - |
Other Investing Activities | - | - | - | -32 | -4 | - |
Investing Cash Flow | 79.78 | -83.28 | 77.54 | -225.19 | -20.79 | -277.61 |
Long-Term Debt Issued | - | 287.5 | 149.55 | - | 363.75 | 314.71 |
Long-Term Debt Repaid | -310.61 | -222.14 | -363.75 | -427.69 | - | -176.79 |
Net Long-Term Debt Issued (Repaid) | -310.61 | 65.37 | -214.2 | -427.69 | 363.75 | 137.92 |
Issuance of Common Stock | 2.5 | 2.3 | 4.75 | 27.34 | 26.66 | 135.56 |
Repurchase of Common Stock | -105.63 | -25.49 | -0.11 | - | - | - |
Net Common Stock Issued (Repurchased) | -103.13 | -23.19 | 4.64 | 27.34 | 26.66 | 135.56 |
Other Financing Activities | -2.2 | -36.06 | -6.91 | -1.18 | -9.71 | -51.17 |
Financing Cash Flow | -319.93 | 17.36 | -183.03 | -401.53 | 380.69 | 222.3 |
Effect of Exchange Rate Changes on Cash and Cash Equivalents | 0.34 | - | - | - | - | - |
Net Cash Flow | 38.57 | 123.48 | 49.16 | -481.44 | 485.62 | 21.73 |
Free Cash Flow | 124.2 | 178.75 | 139.49 | 115.2 | 79.85 | 39.23 |
Free Cash Flow Growth | -30.52% | 28.15% | 21.09% | 44.27% | 103.54% | -35.01% |
FCF Margin | 17.33% | 25.50% | 20.67% | 17.28% | 14.75% | 9.13% |
Free Cash Flow Per Share | 2.68 | 3.87 | 2.68 | 2.48 | 1.75 | 0.90 |
Levered Free Cash Flow | -283.39 | 23.18 | -150.45 | -364.71 | 373.34 | 237.27 |
Unlevered Free Cash Flow | 27.08 | -58.38 | 81.41 | 118.86 | 34.54 | 289.58 |